SHR-2173 / Jiangsu Hengrui Pharma - LARVOL DELTA

A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - P2 | N=248 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Initiation date: Dec 2025 ➔ Mar 2026

Trial initiation date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Subcutaneous Injections of SHR-2173 in Patients with Systemic Lupus Erythematosus (EULAR 2026) - No abstract available

Clinical • P1 data • PK/PD data • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Trial of SHR-2173 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Atridia Pty Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open

A Trial of SHR-2173 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Atridia Pty Ltd.

New P1 trial

SHR-2173-201: Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy (clinicaltrials.gov) - P2 | N=75 | Recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Glomerulonephritis • Renal Disease

A Study of SHR-2173 in Participants With Primary IgA Nephropathy (clinicaltrials.gov) - P2 | N=84 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P2 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease

A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - P2 | N=245 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P2 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy (clinicaltrials.gov) - P2 | N=75 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P2 trial • Glomerulonephritis • Renal Disease

SHR-2173-103: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Active, not recruiting ➔ Completed

Trial completion • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

SHR-2173-204: A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis (clinicaltrials.gov) - P2 | N=51 | Recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

SHR-2173-204: A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis (clinicaltrials.gov) - P2 | N=51 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P2 trial • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P1 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

SHR-2173-103: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting ➔ Active, not recruiting | Trial primary completion date: Jul 2025 ➔ Nov 2025

Enrollment closed • Trial primary completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of SHR-2173 in Healthy Subjects (clinicaltrials.gov) - P1 | N=35 | Completed | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P1 trial